Subtype
Pancreatic Neuroendocrine Neoplasm
CI-CAN-00001357Explore in graph →
Non-malignant36 active trials1 evidence items
- NCIt
- C27031
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001357Explore in graph →
Clinical trials
175 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01824875 | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 144 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03967951 | CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms | completed | — | 70 | Francesco De CobelliOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05997056 | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | completed | Phase 2 | 12 | Aadi Bioscience, Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07695532 | A Clinical Risk Score to Stratify High-risk PanNETs | completed | — | 552 | Fudan UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT00113360 | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | completed | Phase 2 | 36 | Crinetics Pharmaceuticals Inc.INDUSTRY | 7 | Mar 19, 2026 | clinicaltrials |
| NCT03879694 | Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 1 | 19 | Roswell Park Cancer InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07340437 | Clinical Study of 18F-Exendin-4 in Insulinoma | completed | — | 20 | Sichuan Provincial People's HospitalOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02230176 | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II(OCCLURANDOM) | completed | Phase 2 | 84 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT02842749 | Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | completed | Phase 4 | 61 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06024343 | Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction | completed | N/A | 230 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06557408 | Pancreatic Fistula After Minimally Invasive Enucleation | completed | — | 173 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT00970970 | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease(VHLimage) | completed | — | 22 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05476978 | Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions | completed | — | 130 | Huazhong University of Science and TechnologyOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT01525082 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | Shaheen ShaguftaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02264665 | OPALINE : A Study Of Morbidity And Mortality At 2 Years(OPALINE) | completed | — | 144 | PfizerINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06080204 | Real-world Study on Adjuvant Octreotide Therapy in pNETs | completed | N/A | 411 | Changhai HospitalOTHER | 0 | Oct 18, 2023 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00427349 | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05171517 | Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy | completed | — | 200 | Peking Union Medical College HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05800106 | A Bioequivalence Study of Sunitinib Malate Capsules. | completed | Phase 1 | 24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03918759 | Diagnostic Accuracy of Preoperative Diagnostic Procedure in the Assessment of Lymph Node Metastases by NF-PanNENs | completed | — | 100 | IRCCS San RaffaeleOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT04483349 | Assessment of What Patients and Healthcare Providers Value | completed | — | 397 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | completed | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT02358356 | Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study(CONTROL NETS) | completed | Phase 2 | 75 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Jul 5, 2022 | clinicaltrials |
| NCT02586844 | Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors(NET-SEQ) | completed | — | 13 | University Health Network, TorontoOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03147768 | Laser Tissue Welding - Distal Pancreatectomy Sealing Study(LTW) | completed | Phase 1 | 11 | Laser Tissue Welding, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT02420691 | Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02355535 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | completed | Phase 1 | 48 | Vanquish Oncology, Inc.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT02575300 | Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02841865 | Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria(CRIPNET) | completed | — | 104 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT02101918 | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 23, 2020 | clinicaltrials |
| NCT00428220 | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | completed | N/A | 223 | PfizerINDUSTRY | 17 | Jun 27, 2019 | clinicaltrials |
| NCT01603004 | Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors | completed | — | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT02806648 | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)(PALBONET) | completed | Phase 2 | 21 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02685553 | Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project | completed | Phase 1 | 10 | Universita di VeronaOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00093782 | Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00804336 | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 19, 2016 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials